Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) Research & Development (2023 - 2025)

Metagenomi (MGX) has disclosed Research & Development for 3 consecutive years, with $21.5 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 7.18% to $21.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.4 million through Dec 2025, down 13.51% year-over-year, with the annual reading at $94.4 million for FY2025, 13.51% down from the prior year.
  • Research & Development for Q4 2025 was $21.5 million at Metagenomi, down from $25.3 million in the prior quarter.
  • The five-year high for Research & Development was $31.4 million in Q1 2024, with the low at $20.1 million in Q1 2023.
  • Average Research & Development over 3 years is $24.8 million, with a median of $24.9 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 56.18% in 2024, then dropped 20.53% in 2025.
  • Over 3 years, Research & Development stood at $24.8 million in 2023, then decreased by 6.43% to $23.2 million in 2024, then decreased by 7.18% to $21.5 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $21.5 million, $25.3 million, and $22.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.